Ukrainian government to simplify procedure for registration of imported drugs

14 March 2013

The government of Ukraine plans to simplify the procedure of registration of drugs, imported to the country from the European Union. According to an official representative of the Ukrainian State Drugs Service, all the companies, whose drugs are registered by the European Medicines Agency will pass the procedure for their registration in Ukraine only by filing a single application to the country’s Ministry of Health.

If everything goes ahead correctly, the registration procedure of new drugs in Ukraine will not take more than 30 days, compared to the current 120-240 days.

In addition, the adoption of new rules will also allow the start of imports of those drugs to Ukraine which, so far, was impossible due to bureaucratic hurdles. Among them are drugs for the treatment of rare diseases, which are supplied in limited volumes and for which registration has been simply unprofitable.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical